Baxter Phillips III.jpg

Baxter Phillips III

Chief Executive Officer

Baxter has over 20 years of executive experience and a record of success in leading multinational corporate strategy efforts in the biotechnology and pharmaceutical industry. Most recently, Baxter was President and CEO of Neurogastrx, where he successfully led the company to its transformational $45 million Series A financing.

Prior to Neurogastrx, Baxter served as Chief Business Officer of AmpliPhi Biosciences (NYSE: APHB), where he played a pivotal role in establishing the Company’s manufacturing, leading multiple financing campaigns and navigating the company to its NYSE listing. Prior to AmpliPhi, Baxter’s leadership appointments included Depomed, where he was responsible for licensing the company's product portfolio of development-stage and marketed products on a global basis, and Osteologix, where he successfully concluded a global licensing transaction with a multinational pharmaceutical company. Baxter began his career as a research scientist with Insmed, Inc. where for ten years he held a range of leadership positions in research, licensing, finance, investor relations, and sales and marketing. He earned his MBA from the College of William and Mary and his Bachelor of Science in Biology from Hampden-Sydney College.

Jonathan Milner 


After a decade in the life sciences industry as an academic researcher, Jonathan moved to become an experienced entrepreneur and investor. Passionate about supporting UK life science and high-tech start-ups, he is Chairman of Camallergy, as well as Axol Bioscience Ltd, PhoreMost Ltd, Repositive Ltd and Definigen Ltd. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.



Sherden Timmins 

Co-founder and Chief Operating Officer

Sherden led the formation of Camallergy and spin-out from Cambridge University Hospitals following his MBA at the Cambridge Judge Business School. He designed the Cambridge Peanut Allergy Clinic, and led start-up funding rounds and early drug development in preparation for clinical trials. An engineering graduate from Imperial College London and a former management consultant at top-tier firms Booz & Co. (now Strategy&) and Accenture, Sherden has experience across a range of industries in strategy and managing complex and technical programmes.


Dr Pamela Ewan

Consultant Allergist, Addenbrooke’s Hospital, University of Cambridge Clinical School
Co-founder and Chief Medical Officer

Pamela Ewan is one of the leading allergists in the UK and head of the Allergy Department in Cambridge, a leading centre in the specialty. In 1988 she set up the allergy research program at Cambridge University Hospitals, along with the clinical allergy service, which is now one of the largest in the UK.

Pam is experienced in all aspects of clinical allergy. Her special interests are nut allergy, anaphylaxis and venom allergy. She has a large clinical experience in nut allergy. She has been working on nut allergy for 20 years and her research has led to better understanding of this condition and to improvements in patient care. She has developed an effective collaboration with Dr Andrew Clark, and they most recently developed a programme of desensitisation to treat peanut allergy.

In various national roles she worked to highlight the need for allergy care and to improve NHS allergy services, for which she was awarded CBE. She is chair and co-founder of the National Allergy Strategy Group and past President of the British Society for Allergy & Clinical Immunology.


Dr Andrew Clark 

Consultant Allergist, Addenbrooke’s Hospital, University of Cambridge Clinical School
Co-founder and Chief Scientific Officer

Andy has been a consultant in paediatric allergy at Addenbrooke’s Hospital since 2003, gaining his MD Thesis in Allergy in the same year. He runs the paediatric allergy service at Addenbrooke's and this work is complemented by a broad UK Government-funded research portfolio.

In 2010 Andy was named in 'The Times' magazine list of top UK doctors, and again in 2012 he was recognised as one of the UK’s 100 best children’s specialist doctors. He plays an active role in the national parent allergy organisation (BSACI) as chair of the standards of care committee. He recently led writing guideline documents for managing egg allergy and in 2012 he was appointed chair of this committee. He now coordinates the writing of guidelines on multiple topics, such as peanut, milk and penicillin allergy, and adrenaline auto-injector use.

Andy is also secretary to the taskforce on the allergic child in school, which produced European guidelines for school allergy and he is Chair of the expert scientific panel of the Anaphylaxis Campaign.

Andy lectures frequently to undergraduates, primary and secondary care doctors and nurses and is a regular invited speaker at national and European allergy conferences.